Codexis (CDXS) 10-Q 6 Aug 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Aug. 02, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-34705
Entity Registrant Name	Codexis, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	71-0872999
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94063
City Area Code	650
Local Phone Number	421-8100
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	CDXS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		64,640,734
Entity Central Index Key	0001200375
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Address, Address Line One	200 Penobscot Drive

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 129,506	$ 149,117
Restricted cash, current	585	638
Investment in non-marketable debt security	1,289	1,000
Financial assets:
Accounts receivable	19,488	13,894
Contract assets	4,528	4,526
Unbilled receivables	12,417	10,942
Total financial assets	36,433	29,362
Less: allowances	(74)	(74)
Total financial assets, net	36,359	29,288
Inventories	1,078	964
Prepaid expenses and other current assets	3,578	3,416
Total current assets	172,395	184,423
Restricted cash	1,519	1,062
Investment in non-marketable equity securities	3,430	1,450
Right-of-use assets - Operating leases, net	20,124	21,382
Right-of-use assets - Finance leases, net	68	119
Property and equipment, net	11,232	9,675
Goodwill	3,241	3,241
Other non-current assets	301	294
Total assets	212,310	221,646
Current liabilities:
Accounts payable	3,164	2,970
Accrued compensation	6,859	7,288
Other accrued liabilities	9,082	10,272
Current portion of lease obligations - Operating leases	2,672	2,627
Deferred revenue	2,313	1,824
Total current liabilities	24,090	24,981
Deferred revenue, net of current portion	3,166	2,967
Long-term lease obligations - Operating leases	20,992	22,324
Other long-term liabilities	1,289	1,271
Total liabilities	49,537	51,543
Commitments and Contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.0001 par value per share; 100,000 shares authorized; 64,623 shares and 64,283 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	6	6
Additional paid-in capital	542,519	536,516
Accumulated deficit	(379,752)	(366,419)
Total stockholders' equity	162,773	170,103
Total liabilities and stockholders' equity	$ 212,310	$ 221,646

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (shares)	5,000,000	5,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (shares)	100,000,000	100,000,000
Common stock, shares, issued (shares)	64,623,000	64,283,000
Common stock, shares outstanding (shares)	64,623,000	64,283,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues:
Total revenues	$ 25,453	$ 14,967	$ 43,485	$ 29,637
Costs and operating expenses:
Cost of product revenue	4,318	1,699	8,536	4,240
Research and development	12,826	10,853	24,397	21,820
Selling, general and administrative	12,795	8,522	24,193	17,512
Total costs and operating expenses	29,939	21,074	57,126	43,572
Loss from operations	(4,486)	(6,107)	(13,641)	(13,935)
Interest income	206	57	382	323
Other income (expense), net	23	13	(63)	(72)
Loss before income taxes	(4,257)	(6,037)	(13,322)	(13,684)
Provision for income taxes	8	307	11	312
Net loss	$ (4,265)	$ (6,344)	$ (13,333)	$ (13,996)
Net income (loss) per share, basic (usd per share)	$ (0.07)	$ (0.11)	$ (0.21)	$ (0.24)
Net income (loss) per share, diluted (usd per share)	$ (0.07)	$ (0.11)	$ (0.21)	$ (0.24)
Weighted average common stock shares used in computing net income (loss) per share, basic (shares)	64,434	59,000	64,363	58,944
Weighted average common stock shares used in computing net income (loss) per share, diluted (shares)	64,434	59,000	64,363	58,944
Product revenue
Revenues:
Total revenues	$ 14,717	$ 4,504	$ 24,943	$ 9,604
Research and development revenue
Revenues:
Total revenues	$ 10,736	$ 10,463	$ 18,542	$ 20,033

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional paid-in Capital	Accumulated Deficit
Beginning balance (shares) at Dec. 31, 2019		58,877,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (shares)	32,749	32,000
Release of stock awards (shares)		300,000
Taxes paid related to net share settlement of equity awards (shares)		(84,000)
Ending balance (shares) at Jun. 30, 2020		59,125,000
Beginning balance at Dec. 31, 2019	$ 105,517	$ 6	$ 447,920	$ (342,409)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	197		197
Employee stock-based compensation	4,104		4,104
Non-employee stock-based compensation	4		4
Taxes paid related to net share settlement of equity awards	(1,040)		(1,040)
Net income (loss)	(13,996)			(13,996)
Ending balance at Jun. 30, 2020	94,786	$ 6	451,185	(356,405)
Beginning balance (shares) at Mar. 31, 2020		59,017,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (shares)		27,000
Release of stock awards (shares)		81,000
Ending balance (shares) at Jun. 30, 2020		59,125,000
Beginning balance at Mar. 31, 2020	99,066	$ 6	449,121	(350,061)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	158		158
Employee stock-based compensation	1,935		1,935
Non-employee stock-based compensation	4		4
Taxes paid related to net share settlement of equity awards	(33)		(33)
Net income (loss)	(6,344)			(6,344)
Ending balance at Jun. 30, 2020	$ 94,786	$ 6	451,185	(356,405)
Beginning balance (shares) at Dec. 31, 2020		64,283,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (shares)	212,631	213,000
Release of stock awards (shares)		181,000
Taxes paid related to net share settlement of equity awards (shares)		(54,000)
Ending balance (shares) at Jun. 30, 2021		64,623,000
Beginning balance at Dec. 31, 2020	$ 170,103	$ 6	536,516	(366,419)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	1,678		1,678
Employee stock-based compensation	5,405		5,405
Non-employee stock-based compensation	126		126
Taxes paid related to net share settlement of equity awards	(1,206)		(1,206)
Net income (loss)	(13,333)			(13,333)
Ending balance at Jun. 30, 2021	162,773	$ 6	542,519	(379,752)
Beginning balance (shares) at Mar. 31, 2021		64,488,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (shares)		95,000
Release of stock awards (shares)		42,000
Taxes paid related to net share settlement of equity awards (shares)		(2,000)
Ending balance (shares) at Jun. 30, 2021		64,623,000
Beginning balance at Mar. 31, 2021	163,739	$ 6	539,220	(375,487)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	455		455
Employee stock-based compensation	2,779		2,779
Non-employee stock-based compensation	65		65
Net income (loss)	(4,265)			(4,265)
Ending balance at Jun. 30, 2021	$ 162,773	$ 6	$ 542,519	$ (379,752)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities:
Net loss	$ (13,333)	$ (13,996)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,375	900
Amortization expense - right-of-use assets - operating and finance leases	1,309	1,336
Stock-based compensation	5,531	4,108
Equity securities earned from research and development activities	(477)	0
Other non-cash items	(318)	0
Changes in operating assets and liabilities:
Financial assets, net	(7,521)	(6,258)
Inventories	(113)	(315)
Prepaid expenses and other assets	(170)	(824)
Accounts payable	436	(19)
Accrued compensation and other accrued liabilities	(404)	1,839
Other long-term liabilities	(1,314)	(1,270)
Deferred revenue	264	3,001
Net cash used in operating activities	(14,735)	(11,498)
Investing activities:
Purchase of property and equipment	(4,344)	(1,490)
Proceeds from sale of property and equipment	29	0
Payments to acquire other investments	(630)	(1,000)
Net cash used in investing activities	(4,945)	(2,490)
Financing activities:
Proceeds from exercises of stock options	1,679	197
Payments of lease obligations - Finance leases	0	(60)
Taxes paid related to net share settlement of equity awards	(1,206)	(1,040)
Net cash provided by (used in) financing activities	473	(903)
Net decrease in cash, cash equivalents and restricted cash	(19,207)	(14,891)
Cash, cash equivalents and restricted cash at the beginning of the period	150,817	92,221
Cash, cash equivalents and restricted cash at the end of the period	131,610	77,330
Supplemental disclosure of cash flow information:
Interest paid	3	4
Income taxes paid	0	5
Capital expenditures incurred but not yet paid	338	90
Assets received for research and development revenue earned	1,350	0
Cash reconciliation:
Cash and cash equivalents	129,506	75,649
Restricted cash, current and non-current	2,104	1,681
Total cash, cash equivalents and restricted cash	$ 131,610	$ 77,330

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business In these notes to the unaudited condensed consolidated financial statements, the “Company,” “we,” “us,” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis. We discover, develop and sell enzymes and other proteins that deliver value to our clients in a growing set of industries. We view proteins as a vast, largely untapped source of value-creating products, and we are using our proven technologies, which we have been continuously improving since our inception in 2002, to commercialize an increasing number of novel enzymes, both as proprietary Codexis products and in partnership with our customers. We are a pioneer in harnessing computational technologies to drive biology advancements. Since 2002, we have made substantial investments in the development of our CodeEvolver ® protein engineering technology platform, the primary source of our competitive advantage. Our technology platform is powered by proprietary, artificial intelligence-based, computational algorithms that rapidly mine the structural and performance attributes of our large and continuously growing library of protein variants. These computational outputs enable increasingly reliable predictions for next generation protein variants to be engineered, enabling time- and cost-efficient delivery of the targeted performance enhancements. In addition to its computational prowess, our CodeEvolver ® protein engineering technology platform integrates additional modular competencies, including robotic high-throughput screening and genomic sequencing, organic chemistry and bioprocess development which are all coordinated to rapidly innovate novel, fit-for-purpose products. The core historical application of the technology has been in developing commercially viable biocatalytic manufacturing processes for more sustainable production of complex chemicals. This begins by conceptually designing the most cost-effective and practical process for a targeted product. We then develop optimized biocatalysts to enable the designed process, using our CodeEvolver ® platform. Engineered biocatalyst candidates, numbering many thousands for each project, are then rapidly screened and validated using high throughput methods under process-relevant operating conditions. This approach results in an optimized biocatalyst that enables cost-efficient processes that are relatively simple to run in conventional manufacturing equipment. This also allows for efficient technical transfer of our processes to our manufacturing partners. The successful embodiment of our CodeEvolver ® protein engineering technology platform in commercial manufacturing processes requires well-integrated expertise in a number of technical disciplines. In addition to those competencies directly integrated in our CodeEvolver ® protein engineering platform, such as molecular biology, enzymology, microbiology, cellular engineering, metabolic engineering, bioinformatics, biochemistry and high throughput analytical chemistry, our process development projects also involve integrated expertise in organic chemistry, chemical process development, chemical engineering, bioprocess development and fermentation engineering. Our integrated, multi-disciplinary approach to product and process development is a critical success factor for the Company. We initially commercialized our CodeEvolver ® protein engineering technology platform and products in the manufacture of small molecule pharmaceuticals, which remains a primary business focus. Our customers, which include many large, global pharmaceutical companies, use our technology, products and services in their process development and in manufacturing. Additionally, we have licensed our proprietary CodeEvolver ® protein engineering technology platform to global pharmaceutical companies enabling them to use this technology, in house, to engineer enzymes for their own businesses. Most recently, in May 2019, we entered into a Platform Technology Transfer and License Agreement (the “Novartis CodeEvolver ® Agreement”) with Novartis. The Novartis CodeEvolver ® Agreement (our third such agreement with large pharma companies) allows Novartis to use our proprietary CodeEvolver ® protein engineering platform technology in the field of human healthcare. As evidence of our strategy to extend our technology beyond pharmaceutical manufacturing, we have also used the technology to develop biocatalysts and enzyme products for use in a broader set of industrial markets, including several large verticals, such as food, feed, consumer care and fine chemicals. In addition, we are using our technology to develop enzymes for various life science related applications, such as next generation sequencing (“NGS”) and polymerase chain reaction (“PCR/qPCR”) for in vitro molecular diagnostic and genomic research applications. In December 2019, we entered into a license agreement to provide Roche Sequencing Solutions, Inc. with our first enzyme for this target market: the Company’s EvoT4™ DNA ligase. In June 2020, we entered into a co-marketing and enzyme supply collaboration agreement with Alphazyme LLC for the production and co-marketing of enzymes for life science applications including, initially, high-fidelity DNA polymerase, T7 RNA polymerase and reverse transcriptase enzymes. We have been using the CodeEvolver ® protein engineering technology platform to develop early stage, novel biotherapeutic product candidates, both in partnership with customers and for our own proprietary Codexis drug candidates. Our first program was for the potential treatment of phenylketonuria ("PKU") in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we entered into a Global Development, Option and License Agreement (the “Nestlé License Agreement”) with Societé des Produits Nestlé S.A., formerly known as Nestec Ltd. (“Nestlé Health Science”) to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of PKU. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive license to develop and commercialize CDX-6114. Also in October 2017, we entered into a strategic collaboration agreement with Nestlé Health Science (“Nestlé SCA”) pursuant to which we and Nestlé Health Science are collaborating to leverage the CodeEvolver ® platform technology to develop other novel enzymes for Nestlé Health Science’s established Consumer Care and Medical Nutrition business areas. In January 2020, we entered into a development agreement with Nestlé Health Science to advance a new lead candidate discovered under the Nestlé SCA, CDX-7108, into preclinical development and early clinical studies as a potential treatment for a gastrointestinal disorder. In parallel, the Nestlé SCA was extended through December 2021 to support the discovery of therapeutic candidates for additional disorders. In March 2020, we entered into a Strategic Collaboration and License Agreement (“Takeda Agreement”) with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”), for the research and development of novel gene therapies for certain disease indications, including the treatment of lysosomal storage disorders and a blood factor deficiency. In June 2020, we entered into a Master Collaboration and Research Agreement (the “MAI Agreement”) with Molecular Assemblies, Inc ("MAI") pursuant to which we are leveraging our CodeEvolver ® platform technology to improve the DNA polymerase enzymes that are critical for enzymatic DNA synthesis. Concurrently with the MAI Agreement, we entered into a Stock Purchase Agreement with MAI pursuant to which we purchased 1,587,050 shares of MAI's Series A preferred stock for $1.0 million and, in connection with the transaction, John Nicols, our President and Chief Executive Officer, joined MAI’s board of directors. In April 2021, we purchased an additional 1,000,000 shares of MAI's Series A preferred stock for $0.6 million. See Note 12 "Segment, Geographical and Other Revenue Information" for additional information. Below are brief descriptions of our business segments: Performance Enzymes We initially commercialized our CodeEvolver ® protein engineering technology platform and products in the manufacture of small molecule pharmaceuticals and, to date, this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food, feed, consumer care, and fine chemicals. We also use our technology in the life sciences markets to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications, as well DNA/RNA synthesis and health monitoring applications. Novel Biotherapeutics We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver ® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Our first lead program was for the potential treatment of PKU in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we announced a global development, option and license agreement with Nestlé Health Science to advance CDX-6114, our own novel orally administrable enzyme therapeutic candidate for the potential treatment of PKU. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. As a result of the option exercise, we earned a milestone and recognized $3.0 million in revenues in the first quarter of 2019. Upon exercising its option, Nestlé Health Science assumed all responsibilities for future clinical development and commercialization of CDX-6114. In October 2017, we entered into the Nestlé SCA pursuant to which we and Nestlé Health Science are collaborating to leverage the CodeEvolver ® platform technology to develop other novel enzymes for Nestlé Health Science’s established Consumer Care and Medical Nutrition business areas. The Nestlé SCA was extended through December 2021. In January 2020, we and Nestlé Health Science entered into a development agreement pursuant to which we and Nestlé Health Science are collaborating to advance into preclinical and early clinical studies a lead candidate targeting a gastrointestinal disorder, CDX-7108, discovered through the Nestlé SCA. During 2021, we, together with Nestlé Health Science, continued to advance CDX-7108 towards initiation of a Phase 1 clinical trial which we anticipate will begin in the fourth quarter of 2021. Additionally, the parties are progressing three programs under the Nestlé SCA targeting different gastrointestinal disorders. In March 2020, we entered into the Takeda Agreement pursuant to which we are collaborating to research and develop protein sequences for use in gene therapy products for certain disease indications in accordance with the respective program plans for Fabry Disease, Pompe Disease, and an undisclosed blood factor deficiency. In March 2020, we received a one-time, non-refundable cash payment of $8.5 million. Of these programs, the Fabry disease program is the most advanced, with multiple sequences, including CDX-6311, having been provided to Takeda. In May 2021, Takeda elected to exercise their option to expand the collaboration into a fourth program for an undisclosed rare genetic disorder. Business Update Regarding COVID-19 We are subject to risks and uncertainties as a result of the current COVID-19 pandemic. The COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, communities and business operations, as well as the U.S. economy and other economies worldwide. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and may not be accurately predicted, including the duration and severity of the pandemic and the extent and severity of the impact on our customers, new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets. To date, we and our collaboration partners have been able to continue to supply our enzymes to our customers worldwide. However, we are dependent on our manufacturing and logistics partners and consequently, disruptions in operations of our partners and customers may affect our ability to supply enzymes to our customers. Furthermore, our ability to provide future research and development ("R&D") services will continue to be impacted as a result of governmental orders and any disruptions in operations of our customers with whom we collaborate. We believe that these disruptions have had a minimal impact on revenue for the three and six months ended June 30, 2021. The extent to which the pandemic may impact our business operations and operating results will continue to remain highly dependent on future developments, which are uncertain and cannot be predicted with confidence. In the U.S., the impact of COVID-19, including governmental orders ("Orders") governing the operation of businesses during the pandemic, caused the temporary closure of our Redwood City, California facilities and has disrupted our R&D operations. R&D operations for several projects were temporarily suspended from mid-March 2020 through the end of April 2020 in accordance with these Orders. In May 2020, we initiated limited R&D operations and have ramped up operations such that we are currently utilizing the majority of our normal R&D capacity while following county, state and federal COVID-19 guidance for the protection of our employees. Additionally, we resumed manufacturing at our Redwood City pilot plant in May 2020.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information but does not include all the information and notes required by GAAP for complete financial statements. These interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2020. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the Unaudited Condensed Consolidated Financial Statements for the three and six months ended June 30, 2021 and 2020, are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K and are updated below as necessary. There have been no significant changes in our significant accounting policies or critical accounting estimates since December 31, 2020. Certain prior year amounts have been reclassified in the Unaudited Condensed Statements of Cash Flows to conform to the 2021 presentation, however these reclassifications had no effect on the reported results of of operations. The Unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of June 30, 2021, results of our operations for the three and six months ended June 30, 2021 and 2020, changes in stockholders' equity for the three and six months ended June 30, 2021 and 2020, and cash flows for the six months ended June 30, 2021 and 2020. The interim results are not necessarily indicative of the results for any future interim period or for the entire year. The Unaudited Condensed Consolidated Financial Statements include the accounts of Codexis, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, inventories, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, and may not be accurately predicted, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers, markets and economies. Financial Statement Exclusion The net loss in the Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2021 and 2020, is not different from the Unaudited Condensed Consolidated Statements of Comprehensive Loss for the same periods. Accordingly, the Unaudited Condensed Consolidated Financial Statements exclude the Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2021 and 2020. Accounting Pronouncements Recently adopted accounting pronouncements In December 2019, the Financial Accounting Standards Board ("FASB") issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which is intended to simplify various aspects related to accounting for income taxes. We adopted the standard on January 1, 2021, on a modified retrospective basis. The adoption of this standard had no impact on our Unaudited Condensed Consolidated Financial Statements. In October 2020, the FASB issued ASU No. 2020-10, Codification Improvement s. ASU 2020-10 provides amendments to a wide variety of topics in the FASB’s Accounting Standards Codification, which applies to all reporting entities within the scope of the affected accounting guidance. We adopted the standard on January 1, 2021 on a retrospective basis. The adoption of this standard had no impact on our Unaudited Condensed Consolidated Financial Statements. Recently issued accounting pronouncements not yet adopted From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the recently issued standards that are not yet effective will not have a material impact on our Unaudited Condensed Consolidated Financial Statements upon adoption. In May 2021, FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the Emerging Issues Task Force . The standard establishes a principles-based framework in accounting for modifications of freestanding equity-classified written call options on the basis of the economic substance of the underlying transaction. The standard also requires incremental financial statement disclosures. The standard affects entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years with early adoption is permitted by applying the standard as of the beginning of the fiscal year that includes that interim period. The standard may be adopted prospectively for modifications or exchanges occurring on or after the effective date. We will evaluate modifications of equity-classified written call options to determine applicability of the standard on occurrence; however, we believe that the adoption of ASU 2021-04 will have no impact on our Unaudited Condensed Consolidated Financial Statements and related disclosures. In August 2020, FASB issued ASU No. 2020-06 Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40) No. 2020-06 August 2020 Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , to reduce the complexity and to simplify the accounting for convertible debt instruments and convertible preferred stock, and the derivatives scope exception for contracts in an entity's own equity. In addition, the guidance on calculating diluted earnings per share has been simplified and made more internally consistent. The standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years with early adoption permitted for fiscal years beginning December 15, 2020. The standard may be adopted on a modified retrospective or fully retrospective method of transition and on adoption, entities may irrevocably elect the fair value option in accordance with Subtopic 825-10, Financial Instruments—Overall, for any financial instrument that is a convertible security. We believe that the adoption of ASU 2020-06 will have no impact on our Unaudited Condensed Consolidated Financial Statements and related disclosures. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The standard provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions in which the reference LIBOR or another reference rate are expected to be discontinued as a result of the Reference Rate Reform. The standard is effective for all entities and can be adopted no later than December 1, 2022, with early adoption permitted. The standard may be adopted on a prospective basis. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to elect optional expedients for contract modification; however, we believe that the adoption of ASU 2020-04 will have no impact on our Unaudited Condensed Consolidated Financial Statements and related disclosures. There have been no other recent accounting pronouncements or changes in accounting pronouncements during the three and six months ended June 30, 2021, as compared to the recent accounting pronouncements described in herein, that are of significance or potential significance to us.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Disaggregation of Revenue The following table provides information about disaggregated revenue from contracts with customers into the nature of the products and services, and geographic regions, and includes a reconciliation of the disaggregated revenue with reportable segments. The geographic regions that are tracked are the Americas (United States, Canada, and Latin America), EMEA (Europe, Middle East, and Africa), and APAC (Australia, New Zealand, Southeast Asia, and China). Segment information is as follows (in thousands): Three months ended June 30, 2021 Three months ended June 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product Revenue $ 14,717 $ — $ 14,717 $ 4,504 $ — $ 4,504 Research and development revenue 6,868 3,868 10,736 3,002 7,461 10,463 Total revenues $ 21,585 $ 3,868 $ 25,453 $ 7,506 $ 7,461 $ 14,967 Primary geographical markets: Americas 3,703 2,141 $ 5,844 $ 1,173 $ 5,733 $ 6,906 EMEA 4,442 1,727 6,169 1,586 1,728 3,314 APAC 13,440 — 13,440 4,747 — 4,747 Total revenues $ 21,585 $ 3,868 $ 25,453 $ 7,506 $ 7,461 $ 14,967 Six months ended June 30, 2021 Six months ended June 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product Revenue $ 24,943 $ — $ 24,943 $ 9,604 $ — $ 9,604 Research and development revenue 10,872 7,670 18,542 8,775 11,258 20,033 Total revenues $ 35,815 $ 7,670 $ 43,485 $ 18,379 $ 11,258 $ 29,637 Primary geographical markets: Americas $ 6,574 $ 4,199 $ 10,773 $ 4,171 $ 7,960 $ 12,131 EMEA 8,979 3,471 12,450 5,987 3,298 9,285 APAC 20,262 — 20,262 8,221 — 8,221 Total revenues $ 35,815 $ 7,670 $ 43,485 $ 18,379 $ 11,258 $ 29,637 Contract Balances The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands): June 30, 2021 December 31, 2020 Contract assets $ 4,528 $ 4,526 Unbilled receivables $ 12,417 $ 10,942 Contract costs $ 86 $ 90 Contract liabilities: deferred revenue $ 5,479 $ 4,791 We had no asset impairment charges related to financial assets in the three and six months ended June 30, 2021 and 2020. Contract assets remained unchanged as of June 30, 2021 and December 31, 2020. The increase in unbilled receivables was primarily due to the timing of billings. The increase in deferred revenue was primarily due to cash advances received in excess of revenue recognized. We recognized the following revenues (in thousands): Three months ended June 30, Six months ended June 30, Revenue recognized in the period for: 2021 2020 2021 2020 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 1,239 $ 4,272 $ 1,391 $ 57 Changes in the period: Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods 4,306 1,357 4,336 637 Performance obligations satisfied from new activities in the period - contract revenue 19,908 9,338 37,758 28,943 Total revenues $ 25,453 $ 14,967 $ 43,485 $ 29,637 Performance Obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of June 30, 2021. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of June 30, 2021 (in thousands): Remainder of 2021 2022 2023 2024 and Thereafter Total Product revenue $ — $ 67 $ 67 $ 1,843 $ 1,977 Research and development revenue 1,568 1,388 546 — 3,502 Total revenues $ 1,568 $ 1,455 $ 613 $ 1,843 $ 5,479

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Loss per Share	N et Loss per S hare Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding, less restricted stock awards (“RSAs”) subject to forfeiture. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock shares outstanding, less RSAs subject to forfeiture, plus all additional common shares that would have been outstanding, assuming dilutive potential common stock shares had been issued for other dilutive securities. Anti-Dilutive Securities In periods of net loss, the weighted average number of shares outstanding, prior to the application of the treasury stock method, excludes potentially dilutive securities from the computation of diluted net loss per common share because including such shares would have an anti-dilutive effect. The following shares were not considered in the computation of diluted net loss per share because their effect was anti-dilutive (in thousands): Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Shares issuable under the Equity Incentive Plan 5,366 5,289 5,366 5,289

Investments in Non-Marketable S

Investments in Non-Marketable Securities	6 Months Ended
	Jun. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Investments in Non-Marketable Securities	Investments in Non-Marketable Securities Non-Marketable Debt Securities We classify non-marketable debt securities, which are accounted for as available-for-sale, within Level 3 in the fair value hierarchy because we estimate the fair value based on a qualitative analysis using the most recent observable transaction price and other significant unobservable inputs including volatility, rights, and obligations of the securities we hold. We determine gains or losses on the sale or extinguishment of non-marketable debt securities using a specific identification method. Unrealized gains and losses from bifurcated embedded derivatives, which represent share-settled redemption features, are recorded as other expense, net, in the unaudited condensed consolidated statements of operations. Unrealized gains and losses on non-marketable debt securities are recorded as a component of other comprehensive loss until realized. Realized gains or losses are recorded as a component of other income (expense), net. In the three and six months ended June 30, 2021, we recognized $0.2 million and $0.3 million, respectively, in interest income from amortization of debt discount and interest earned on our investment in non-marketable debt security, and $57.5 thousand in other income and $10.5 thousand in other expense , respectively, in other income (expense), net, on the change in the fair value of an embedded bifurcated derivative. We recognized no unrealized or realized gains or losses during the three and six months ended June 30, 2021. We recognized no interest income, other expenses, and unrealized or realized gains or losses during the three and six months ended June 30, 2020. The following table presents balances of the adjusted cost and carrying value and fair value of non-marketable debt security by contractual maturity (in thousands): June 30, 2021 Adjusted Cost and Carrying Value Fair Value Non-marketable debt security due in 1 year or less $ 1,289 $ 1,289 December 31, 2020 Adjusted Cost and Carrying Value Fair Value Non-marketable debt security due in 1 year or less $ 1,000 $ 1,000 Non-Marketable Equity Securities Non-marketable equity securities are investments in privately held companies without readily determinable market value. We measure investments in non-marketable equity securities without a readily determinable fair value using a measurement alternative that measures these securities at the cost method minus impairment, if any, plus or minus changes resulting from observable price changes on a non-recurring basis. The fair value of non-marketable equity securities that have been remeasured due to impairment are classified within Level 3. We adjust the carrying value of non-marketable equity securities which have been remeasured during the period and recognize resulting gains or losses as a component of other income (expense), net. We recognized no unrealized or realized gain or losses during the three and six months ended June 30, 2021 and 2020. The following table presents balances of the carrying value of non-marketable equity securities (in thousands): June 30, 2021 December 31, 2020 Non-marketable equity securities $ 3,430 $ 1,450

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables present the financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands): June 30, 2021 Level 1 Level 2 Level 3 Total Money market funds $ 111,083 $ — $ — $ 111,083 Non-marketable debt security — — 1,289 1,289 Total $ 111,083 $ — $ 1,289 $ 112,372 December 31, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 127,567 $ — $ — $ 127,567 Non-marketable debt security — — 1,000 1,000 Total $ 127,567 $ — $ 1,000 $ 128,567 The fair value of non-marketable securities remeasured due to impairment would be classified within Level 3. During the three and six months ended June 30, 2021 and 2020, we did not recognize any significant credit losses nor other-than-temporary impairment losses on non-marketable securities. The carrying value of our non-marketable securities approximated fair value.

Balance Sheets Details

Balance Sheets Details	6 Months Ended
	Jun. 30, 2021
Balance Sheets Details [Abstract]
Balance Sheets Details	Balance Sheets Details Cash Equivalents Cash equivalents as of June 30, 2021 and December 31, 2020, consisted of the following (in thousands): June 30, 2021 December 31, 2020 Adjusted Cost Estimated Fair Value Adjusted Cost Estimated Fair Value Money market funds (1) $ 111,083 $ 111,083 $ 127,567 $ 127,567 (1) Money market funds are classified in cash and cash equivalents on our consolidated balance sheets. Average Contractual Maturities (in days) is not applicable. As of June 30, 2021, the total cash and cash equivalents balance of $129.5 million was comprised of money market funds of $111.1 million and cash of $18.4 million held with major financial institutions. As of December 31, 2020, the total cash and cash equivalents balance of $149.1 million was comprised of money market funds of $127.6 million and cash of $21.5 million held with major financial institutions. Inventories Inventories consisted of the following (in thousands): June 30, 2021 December 31, 2020 Raw materials $ 49 $ 77 Work-in-process 98 82 Finished goods 931 805 Inventories $ 1,078 $ 964 Inventories includes reserves of $1.5 million as of June 30, 2021 and December 31, 2020. Property and Equipment, net Property and equipment, net consisted of the following (in thousands): June 30, 2021 December 31, 2020 Laboratory equipment $ 28,623 $ 25,468 Leasehold improvements 10,785 10,785 Computer equipment and software 3,283 3,192 Office equipment and furniture 1,246 1,246 Construction in progress 1,736 2,357 Property and equipment 45,673 43,048 Less: accumulated depreciation and amortization (34,441) (33,373) Property and equipment, net $ 11,232 $ 9,675 Depreciation expense included in the Unaudited Condensed Consolidated Statements of Operations was follows (in thousands): Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Depreciation Expense $ 716 $ 462 $ 1,375 $ 900 Goodwill Goodwill had a carrying value of $3.2 million as of June 30, 2021 and December 31, 2020. Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands): June 30, 2021 December 31, 2020 Accrued purchases $ 5,107 $ 7,170 Accrued professional and outside service fees 3,899 2,589 Other 76 513 Total $ 9,082 $ 10,272

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation Equity Incentive Plans In 2019, our board of directors (the "Board") and stockholders approved the 2019 Incentive Award Plan (the "2019 Plan"). The 2019 Plan superseded and replaced in its entirety our 2010 Equity Incentive Plan (the “2010 Plan”) which was effective in March 2010, and no further awards will be granted under the 2010 Plan; however, the terms and conditions of the 2010 Plan will continue to govern any outstanding awards thereunder. The 2019 Plan provides for the grant of stock options, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock awards ("RSAs"), restricted stock units ("RSUs"), performance-contingent restricted stock units ("PSUs"), performance based options ("PBOs"), other stock or cash based awards and dividend equivalents to eligible employees and consultants of the Company or any parent or subsidiary, as well as members of the Board. The number of shares of our common stock available for issuance under the 2019 Plan is equal to the sum of (i) 7,897,144 shares, and (ii) any shares subject to awards granted under the 2010 Plan that were outstanding as of April 22, 2019 and thereafter terminate, expire, lapse or are forfeited; provided that no more than 14,000,000 shares may be issued upon the exercise of incentive stock options (“ISOs”). In June 2019, 8.1 million shares authorized for issuance under the 2019 Plan were registered under the Securities Act of 1933, as amended (the “Securities Act”). The 2010 Plan provided for the grant of incentive stock options, non-statutory stock options, RSUs, RSAs, PSUs, PBOs, stock appreciation rights, and stock purchase rights to our employees, non-employee directors and consultants. Stock Options The option exercise price for incentive stock options must be at least 100% of the fair value of our common stock on the date of grant and the option exercise price for non-statutory stock options is at least 85% of the fair value of our common stock on the date of grant, as determined by the Board. If, at the time of a grant, the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all of our outstanding capital stock, the exercise price for these options must be at least 110% of the fair value of the underlying common stock. Stock options granted to employees generally have a maximum term of ten years and vest over four years from the date of grant, of which 25% vest at the end of one year, and 75% vest monthly over the remaining three years. We may grant options with different vesting terms from time to time. Unless an employee's termination of service is due to disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of three months or the expiration of the option, whichever is earlier. Restricted Stock Units ("RSUs") We also grant employees RSUs, which generally vest over either a three year period with 33% of the shares subject to the RSUs vesting on each yearly anniversary of the vesting commencement date or over a four year period with 25% of the shares subject to the RSU vesting on each yearly anniversary of the vesting commencement date, in each case contingent upon such employee’s continued service on such vesting date. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. We may grant RSUs with different vesting terms from time to time. Performance-contingent Restricted Stock Units ("PSUs") and Performance Based Options ("PBOs") The compensation committee of the Board approved, solely in respect of non-executive employees, delegated to our Chief Executive Officer the authority to approve grants of PSUs. The compensation committee of the Board also approved grants of PBOs and PSUs to our executives. The PSUs and PBOs vest based upon both the successful achievement of certain corporate operating milestones in specified timelines and continued employment through the applicable vesting date. When the performance goals are deemed to be probable of achievement for these types of awards, recognition of stock-based compensation expense commences. Once the number of shares eligible to vest is determined, those shares vest in two equal installments with 50% vesting upon achievement and the remaining 50% vesting on the first anniversary of achievement, in each case, subject to the recipient’s continued service through the applicable vesting date. If the performance goals are achieved at the threshold level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to half the number of PSUs granted and one-quarter the number of shares underlying the PBOs granted. If the performance goals are achieved at the target level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to the number of PSUs granted and half of the shares underlying the PBOs granted. If the performance goals are achieved at the superior level, the number of shares eligible to vest in respect of the PSUs would be equal to two times the number of PSUs granted and equal to the number of PBOs granted. The number of shares issuable upon achievement of the performance goals at the levels between the threshold and target levels for the PSUs and PBOs or between the target level and superior levels for the PSUs would be determined using linear interpolation. Achievement below the threshold level would result in no shares being eligible to vest in respect of the PSUs and PBOs. In the first quarter of 2021, we awarded PSUs ("2021 PSUs") and PBOs ("2021 PBOs"), each of which commence vesting based upon the achievement of various weighted performance goals, including corporate revenue, performance enzyme segment gross margin, major new biotherapeutics publicity events, strategic performance enzyme and biotherapeutics deliverables, safety, and technology and strategic plan development. As of June 30, 2021, we estimated that the 2021 PSUs and 2021 PBOs performance goals would be achieved at 136% and 68% of the target level, respectively, and recognized expenses accordingly. In 2020, we awarded PSUs ("2020 PSUs") and PBOs ("2020 PBOs"), each of which commenced vesting based upon the achievement of various weighted performance goals, including corporate revenue, performance enzyme segment gross margin, major new biotherapeutics publicity events, strategic performance enzyme and biotherapeutics deliverables, and strategic plan development. In the first quarter of 2021, we determined that the 2020 PSUs and 2020 PBOs performance goals had been achieved at 88% of the target level, and recognized expenses accordingly. Accordingly, 50% of the shares underlying the 2020 PSUs and PBOs vested in the first quarter of 2021 and 50% of the shares underlying the 2020 PSUs and PBOs will vest in the first quarter of 2022, in each case, subject to the recipient’s continued service on each vesting date. In 2019, we awarded PSUs ("2019 PSUs") and PBOs ("2019 PBOs"), each of which commenced vesting based upon the achievement of various weighted performance goals, including sustained revenue and performance enzyme growth, strategic advancement of biotherapeutics, cash balance and strategic plan development. In the first quarter of 2020, we determined that the 2019 PSUs and 2019 PBOs performance goals had been achieved at 84% of the target level, and recognized expenses accordingly. Accordingly, 50% of the shares underlying the 2019 PSUs and PBOs vested in the first quarter of 2020 and 50% of the shares underlying the 2019 PSUs and PBOs vested in the first quarter of 2021, in each case, subject to the recipient’s continued service on each vesting date. Stock-Based Compensation Expense Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Research and development $ 597 $ 471 $ 1,074 $ 894 Selling, general and administrative 2,247 1,468 4,457 3,214 Total $ 2,844 $ 1,939 $ 5,531 $ 4,108 The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Stock options $ 682 $ 575 $ 1,347 $ 1,116 RSUs and RSAs 690 610 1,232 1,210 PSUs 573 296 1,043 627 PBOs 899 458 1,909 1,155 Total $ 2,844 $ 1,939 $ 5,531 $ 4,108 As of June 30, 2021 , unrecognized stock-based compensation expense, net of expected forfeitures, was $4.8 million related to unvested stock options, $4.7 million related to unvested RSUs and RSAs, $1.9 million re lated to unvested PSUs, and $3.3 million related to unvested PBOs based on current estimates of the level of achievement. Stock-based compensation ex pense for these awards will be recognized through the year o f 2025.

Capital Stock

Capital Stock	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Capital Stock	Capital Stock Exercise of Options For the six months ended June 30, 2021 and June 30, 2020, we issued 212,631 and 32,749 shares, respectively, upon option exercises at a weighted-average exercise price of $8.03 and $6.03 per share, respectively, with net cash proceeds of $1.7 million and $0.2 million, respectively. Equity Distribution Agreement We filed a Registration Statement on Form S-3 with the SEC, under which we may sell common stock, preferred stock, debt securities, warrants, purchase contracts, and units from time to time in one or more offerings. The registration statement became effective on May 7, 2021. In May 2021, we entered into an Equity Distribution Agreement ("EDA") with Piper Sandler & Co ("PSC"), under which PSC, as our exclusive agent, at our discretion and at such times that we may determine from time to time, may sell over a three-year period from the execution of the EDA up to a maximum of $50.0 million of shares of our common stock. Under the terms of the EDA, PSC may sell the shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended. We are not required to sell any shares at any time during the term of the EDA. The EDA will terminate upon the earlier of: (i) the issuance and sale of all shares through PSC on the terms and conditions of the EDA, or (ii) the termination of the EDA in accordance with its terms. Either party may terminate the EDA at any time upon written notification to the other party in accordance with the EDA, and upon such notification, the offering will terminate. Under no circumstances shall any shares be sold pursuant to the EDA after the date which is three years after the registration statement is first declared effective by the SEC. We agreed to pay PSC a commission of 3% of the gross sales price of any shares sold pursuant to the EDA. With the exception of certain expenses, we will pay PSC up to 8% of the gross sales price of the shares sold pursuant to the EDA for a combined amount of commission and reimbursement of PSC's expenses and fees.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases Our headquarters are located in Redwood City, California, where we occupy approximately 77,300 square feet of office and laboratory space in multiple buildings within the same business park of Metropolitan Life Insurance Company ("MetLife"). Our lease agreement with MetLife ("RWC Lease") includes approximately 28,200 square feet of space located at 200 and 220 Penobscot Drive, Redwood City, California (the “200/220 Penobscot Space”) and approximately 37,900 square feet of space located at 400 Penobscot Drive, Redwood City, California (the “400 Penobscot Space”) (the 200/220 Penobscot Space and the 400 Penobscot Space are collectively referred to as the “Penobscot Space”), and approximately 11,200 square feet of space located at 501 Chesapeake Drive, Redwood City, California (the “501 Chesapeake Space”). Until the end of January 2020, we also leased approximately 29,900 square feet of space located at 101 Saginaw Drive, Redwood City, California (the “Saginaw Space”). During January 2020, we subleased approximately 26,500 square feet of the Saginaw Space to Minerva Surgical, Inc. The lease and sublease for the Saginaw Space both expired at the end of January 2020. During the period from February 1, 2020 through April 30, 2020, we subleased approximately 3,400 square feet at 101 Saginaw Drive from Minerva Surgical, Inc. The sublease expired at the end of April 2020. We entered into the initial lease with MetLife for our facilities in Redwood City in 2004 and the RWC Lease has been amended multiple times since then to adjust the leased space and terms of the Lease. In February 2019, we entered into an Eighth Amendment to the Lease (the “Eighth Amendment”) with MetLife with respect to the Penobscot Space and the 501 Chesapeake Space to extend the term of the Lease for additional periods. Pursuant to the Eighth Amendment, the term of the lease of the Penobscot Space has been extended through May 2027. The lease term for the 501 Chesapeake Space has been extended to May 2029. We have one (1) option to extend the term of the lease for the Penobscot Space for five (5) years, and one (1) separate option to extend the term of the lease for the 501 Chesapeake Space for five (5) years. We are required to restore certain areas of the Redwood City facilities that we are renting to their original form. We are expensing the asset retirement obligation over the terms of the respective leases. We review the estimated obligation each reporting period and make adjustments if our estimates change. We recorded asset retirement obligations of $0.2 million as of June 30, 2021 and December 31, 2020, which are included in other long-term liabilities in the unaudited condensed consolidated balance sheets. Accretion expense related to our asset retirement obligations was nominal in the three and six months ended June 30, 2021 and 2020. Pursuant to the terms of the RWC Lease, we exercised our right to deliver a letter of credit in lieu of a security deposit. The letter of credit is collateralized by deposit balances held by the bank in the amount of $1.1 million as of June 30, 2021 and December 31, 2020, and are recorded as non-current restricted cash on the unaudited condensed consolidated balance sheets. We entered into a short-term office lease in San Carlos, California during the second quarter of 2021 and this lease will expire in April 2022. Our remaining future commitment pursuant to this lease is $0.1 million as of June 30, 2021. Finance Leases In December 2016, we entered into a three-year financing lease agreement with a third party supplier for the purchase of laboratory equipment that was partially financed through a finance lease of $0.4 million. The lease became effective upon delivery of the equipment in February 2017, and the term of the three-year lease was from February 2017 and expired in February 2020. This financing agreement was accounted for as a finance lease due to bargain purchase options at the end of the lease. In April 2017, we entered into a three-year financing lease agreement with a third-party supplier for the purchase of information technology equipment for $0.3 million. The effective term of the three-year lease was from May 2017 and expired in April 2020. Lease and other information Lease costs, amounts included in measurement of lease obligations and other information related to non-cancellable operating leases and finance leases were as follows (in thousands): Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Finance lease costs: Amortization of right-of-use assets $ 27 $ 45 $ 53 $ 99 Interest on lease obligations — 1 — 1 Finance lease costs 27 46 53 100 Operating lease cost 1,033 1,032 2,065 2,100 Short-term lease costs (1) 10 16 10 47 Sublease income — — — (55) Total lease cost (2) $ 1,070 $ 1,094 $ 2,128 $ 2,192 (1 ) Short-term lease costs on leases with terms of over one month and less than one year. (2) The Company had no variable lease costs. Other information: Operating Leases Weighted-average remaining lease term (in years) 6.2 years Weighted-average discount rate 6.6 % Six months ended June 30, Cash paid: 2021 2020 Operating cash flows from operating leases $ 2,093 $ 774 Financing cash flows from finance leases $ — $ 60 As of June 30, 2021, our maturity analysis of annual undiscounted cash flows of the non-cancellable operating leases are as follows (in thousands): Years ending December 31, Operating Leases 2021 (remaining 6 months) $ 2,104 2022 4,285 2023 4,589 2024 4,726 2025 4,868 Thereafter 8,626 Total minimum lease payments 29,198 Less: imputed interest 5,534 Lease obligations $ 23,664 Future Lease Commitment In the first quarter of 2021, we entered into a lease agreement with ARE-San Francisco No. 63, LLC (“ARE”) to lease a portion of a facility comprising approximately 36,593 rentable square feet in San Carlos, California to serve as additional office and research and development laboratory space (the “San Carlos Space”). We expect to commence occupancy of the San Carlos Space in November 2021 once tenant improvements are substantially completed by ARE in accordance with the construction plan. The budget provides a net tenant improvement allowance of $6.3 million and an additional allowance of up to $2.7 million, which we expect to use. ARE will have an enforceable right to payment by us in the form of equal monthly additional rent payments at a certain interest rate through the lease term for the additional allowance. The terms include an initial annualized base rent of $2.5 million, subject to scheduled 3% annual rent increases, an annualized additional allowance payment of $0.4 million, plus certain operating expenses. The lease has a 10-year term from the lease commencement date with one option to extend the term for an additional period of 5 years. We have provided ARE with a $0.5 million security deposit in the form of a letter of credit. We have the right to sublease the facility, subject to landlord consent. We determined that the lease commencement date is in November 2021 at which point we will record a right of use asset and a corresponding lease liability. An estimated maturity analysis of the annual undiscounted cash flows of the lease is as follows (in thousands): Years ending December 31, Operating Lease 2021 (remaining 6 months) $ — 2022 2,463 2023 2,988 2024 3,066 2025 3,145 2026 and thereafter 20,061 Total minimum lease payments $ 31,723 Other Commitments We enter into supply and service arrangements in the normal course of business. Supply arrangements are primarily for fixed-price manufacture and supply. Service agreements are primarily for the development of manufacturing processes and certain studies. Commitments under service agreements are subject to cancellation at our discretion which may require payment of certain cancellation fees. The timing of completion of service arrangements is subject to variability in estimates of the time required to complete the work. The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands): Other Commitment Agreement Type Agreement Date Future Minimum Payment Manufacture and supply agreement with expected future payment date of December 2022 April 2016 $ 162 Development and manufacturing services agreements September 2019 1,852 Total other commitments $ 2,014 Credit Facility In June 30, 2017, we entered into a credit facility (the “Credit Facility”) with Western Alliance Bank consisting of term loans (“Term Debt”) up to $10.0 million, and advances (“Advances”) under a revolving line of credit ("Revolving Line of Credit") up to $5.0 million with an accounts receivable borrowing base of 80% of eligible accounts receivable. As of June 30, 2021 and December 31, 2020, we have not drawn from the Credit Facility. We may draw on the Term Debt and the Revolving Line of Credit at any time prior to October 1, 2021 and October 1, 2024, respectively. On October 1, 2024 loans drawn under the Term Debt mature and the Revolving Line of Credit terminate. Loans made under the Term Debt bear interest through maturity equal to the greater of (i) 3.75% or (ii) the sum of (A) Index Rate (prime rate published in the Money Rates section of the Western Edition of The Wall Street Journal plus (B) 0.50%. Advances made under the Revolving Line of Credit bear interest at a variable annual rate equal to the equal to the greater of (i) 4.25% or (ii) the sum of (A) the prime rate plus (B) 1.00%. Our obligations under the Credit Facility are secured by a lien on substantially all of our personal property other than our intellectual property. The Credit Facility includes a number of customary covenants and restrictive financial covenants including meeting minimum product revenue levels and maintaining certain minimum cash levels with the lender. The Credit Facility's financial covenants restrict the ability of the Company to transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets, or sell certain assets held at foreign subsidiaries. A failure to comply with these covenants could permit the lender to exercise remedies against us and the collateral securing the Credit Facility, including foreclosure of our properties securing the Credit Facilities and our cash. As of June 30, 2021, we were in compliance with the covenants for the Credit Facility. The Credit Facility allows for interest-only payments on the Term Debt through November 1, 2022. Monthly payments of principal and interest on the Term Debt are required following the applicable amortization date. We may elect to prepay in full the Term Debt and Advances under the Revolving Line of Credit at any time. Legal Proceedings We are not currently a party to any material pending litigation or other material legal proceedings. Indemnifications We are required to recognize a liability for the fair value of any obligations we assume upon the issuance of a guarantee. We have certain agreements with licensors, licensees and collaborators that contain indemnification provisions. In such provisions, we typically agree to indemnify the licensor, licensee and collaborator against certain types of third party claims. The maximum amount of the indemnifications is not limited. We accrue for known indemnification issues when a loss is probable and can be reasonably estimated. There were no accruals for expenses related to indemnification issues for any periods presented.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Molecular Assemblies, Inc. In June 2020, we entered into a Stock Purchase Agreement with MAI pursuant to which we purchased 1,587,050 shares of MAI's Series A preferred stock for $1.0 million. In connection with the transaction, John Nicols, our President and Chief Executive Officer, also joined MAI’s board of directors. Concurrently with our initial equity investment, we entered into the MAI Agreement with MAI, pursuant to which we are performing services utilizing our CodeEvolver ® protein engineering platform technology to improve DNA polymerase enzymes in exchange for compensation in the form of additional shares of MAI's Series A preferred stock. In April 2021, we purchased an additional 1,000,000 shares of MAI's Series A preferred stock for $0.6 million. We recognized $0.3 million and $0.5 million in research and development revenue from transactions with MAI in the three and six months ended June 30, 2021, respectively, and we recognized no revenue from research and development service transactions with MAI in the three and six months ended June 30, 2020. We received 714,171 and 1,428,342 shares of MAI's Series A preferred stock from research and development services we provided to MAI in the three and six months ended June 30, 2021, respectively, and no shares of MAI's Series A preferred stock from research and development services in the three and six months ended June 30, 2020. As of June 30, 2021, we have 5,443,734 shares of MAI's Series A preferred stock since executing the Stock Purchase Agreement with MAI. The carrying value of our investment in MAI Series A preferred stock was $3.4 million and $1.5 million at June 30, 2021 and December 31, 2020, respectively. We had $0.4 million and nil in deferred revenue as of June 30, 2021 and December 31, 2020, respectively, and nil and $0.5 million in contract asset due from MAI for services rendered as of June 30, 2021 and December 31, 2020, respectively. Payment for the services rendered was received in the form of additional MAI Series A preferred stock. AstraZeneca PLC Pam P. Cheng, who served as a member of our board of directors until June 2020, joined AstraZeneca PLC as Executive Vice President, Operations and Information Technology in June 2015. We sold biocatalyst products to AstraZeneca PLC and its controlled purchasing agents and contract manufacturers. We recognized $20 thousand and $0.1 million of revenue from transactions with AstraZeneca and its controlled purchasing agents and contract manufacturers for the three and six months ended June 30, 2020, respectively, and through the date of Ms. Cheng’s departure from our board of directors. As of June 30, 2021 and December 31, 2020, we had no receivables from AstraZeneca PLC and its controlled purchasing agents and contract manufacturers from related party transactions, respectively.

Segment, Geographical and Other

Segment, Geographical and Other Revenue Information	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Segment, Geographical and Other Revenue Information	Segment, Geographical and Other Revenue Information Segment Information We manage our business as two business segments: Performance Enzymes and Novel Biotherapeutics. Our chief operating decision maker ("CODM") is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company. We report corporate-related expenses such as legal, accounting, information technology, and other costs that are not otherwise included in our reportable business segments as "Corporate costs." All items not included in income (loss) from operations are excluded from the business segments. We manage our assets on a total company basis, not by business segment, as the majority of our operating assets are shared or commingled. Our CODM does not review asset information by business segment in assessing performance or allocating resources, and accordingly, we do not report asset information by business segment. Performance Enzymes We initially commercialized our CodeEvolver ® protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications. Novel Biotherapeutics We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver ® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Most notable is our lead program for the potential treatment of PKU in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. We have also developed a pipeline of other biotherapeutic drug candidates, which are in preclinical development, and in which we expect to continue to make additional investments with the aim of advancing additional product candidates targeting other therapeutic areas. In March 2020, we entered into the Takeda Agreement with Takeda under which we will research and develop protein sequences for use in gene therapy products for certain diseases. Factors considered in determining the two reportable segments of the Company include the nature of business activities, the management structure directly accountable to our CODM for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors. Our CODM regularly reviews our segments and the approach provided by management for performance evaluation and resource allocation. Operating expenses that directly support the segment activity are allocated based on segment headcount, revenue contribution or activity of the business units within the segments, based on the corporate activity type provided to the segment. The expense allocation excludes certain corporate costs that are separately managed from the segments. This provides the CODM with more meaningful segment profitability reporting to support operating decisions and allocate resources. The following table provides financial information by our reportable business segments along with a reconciliation to consolidated income (loss) before income taxes (in thousands): Three months ended June 30, 2021 Three months ended June 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 14,717 $ — $ 14,717 $ 4,504 $ — $ 4,504 Research and development revenue 6,868 3,868 10,736 3,002 7,461 10,463 Total revenues 21,585 3,868 25,453 7,506 7,461 14,967 Costs and operating expenses: Cost of product revenue 4,318 — 4,318 1,699 — 1,699 Research and development (1) 5,057 7,194 12,251 4,997 5,490 10,487 Selling, general and administrative (1) 3,170 620 3,790 2,375 621 2,996 Total segment costs and operating expenses 12,545 7,814 20,359 9,071 6,111 15,182 Income (loss) from operations $ 9,040 $ (3,946) 5,094 $ (1,565) $ 1,350 (215) Corporate costs (2) (8,610) (5,316) Unallocated depreciation and amortization (741) (506) Loss before income taxes $ (4,257) $ (6,037) Six months ended June 30, 2021 Six months ended June 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 24,943 $ — $ 24,943 $ 9,604 $ — $ 9,604 Research and development revenue 10,872 7,670 18,542 8,775 11,258 20,033 Total revenues 35,815 7,670 43,485 18,379 11,258 29,637 Costs and operating expenses: Cost of product revenue 8,536 — 8,536 4,240 — 4,240 Research and development (1) 11,502 11,799 23,301 10,693 10,415 21,108 Selling, general and administrative (1) 5,988 1,221 7,209 4,720 1,213 5,933 Total segment costs and operating expenses 26,026 13,020 39,046 19,653 11,628 31,281 Income (loss) from operations $ 9,789 $ (5,350) 4,439 $ (1,274) $ (370) (1,644) Corporate costs (2) (16,335) (11,042) Unallocated depreciation and amortization (1,426) (998) Loss before income taxes $ (13,322) $ (13,684) (1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases. (2) Corporate costs include unallocated selling, general and administrative expenses, interest income, and other income (expense), net. The following table provides stock-based compensation expense included in income (loss) from operations (in thousands): Three months ended June 30, 2021 2020 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 1,115 $ 257 $ 1,472 $ 2,844 $ 741 $ 252 $ 946 $ 1,939 Six months ended June 30, 2021 2020 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 2,109 $ 495 $ 2,927 $ 5,531 $ 1,496 $ 494 $ 2,118 $ 4,108 Significant Customers Customers that each accounted for 10% or more of our total revenues were as follows: Percentage of Total Revenues for the Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Customer A 15% * 10% * Customer B 12% * * * Customer C 12% * 13% * Customer D * 16% 17% 20% Customer E * 38% 10% 27% Customer F * 12% * 11% Customer G * * * 13% * Percentage was less than 10% Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows: Percentage of Accounts Receivables as of June 30, 2021 December 31, 2020 Customer A 20% * Customer H 15% * Customer B 15% * Customer D 14% 32% Customer E 10% * Customer G * 25% Customer F * 13% * Percentage was less than 10% Geographical Information Geographic revenues are identified by the location of the customer and consist of the following (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenues Americas $ 5,844 $ 6,906 $ 10,773 $ 12,131 EMEA 6,169 3,314 12,450 9,285 APAC 13,440 4,747 20,262 8,221 Total revenues $ 25,453 $ 14,967 $ 43,485 $ 29,637 Identifiable long-lived assets by location was as follows (in thousands): June 30, 2021 December 31, 2020 United States $ 31,424 $ 31,176 Identifiable goodwill by reporting unit was as follows (in thousands): As of June 30, 2021 and December 31, 2020 Performance Enzymes Novel Biotherapeutics Total Goodwill $ 2,463 $ 778 $ 3,241

Allowance for Credit Losses

Allowance for Credit Losses	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
Allowance for Credit Losses	Allowance for Credit Losses The following table summarizes the financial assets allowance for credit losses (in thousands): June 30, 2021 December 31, 2020 Allowance for credit losses $ 74 74 The following tables summarize accounts receivable by aging category (in thousands): June 30, 2021 Current 31-60 Days 61-90 Days 91 Days and over Total balance Accounts receivable $ 17,414 $ 83 $ 1,602 $ 389 $ 19,488 December 31, 2020 Current 31-60 Days 61-90 Days 91 Days and over Total balance Accounts receivable $ 13,398 $ 489 $ 7 $ — $ 13,894

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information but does not include all the information and notes required by GAAP for complete financial statements. These interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2020. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the Unaudited Condensed Consolidated Financial Statements for the three and six months ended June 30, 2021 and 2020, are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K and are updated below as necessary. There have been no significant changes in our significant accounting policies or critical accounting estimates since December 31, 2020. Certain prior year amounts have been reclassified in the Unaudited Condensed Statements of Cash Flows to conform to the 2021 presentation, however these reclassifications had no effect on the reported results of of operations. The Unaudited Condensed Consolidated Financial Statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of June 30, 2021, results of our operations for the three and six months ended June 30, 2021 and 2020, changes in stockholders' equity for the three and six months ended June 30, 2021 and 2020, and cash flows for the six months ended June 30, 2021 and 2020. The interim results are not necessarily indicative of the results for any future interim period or for the entire year.
Use of Estimates	Use of Estimates The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, inventories, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, and may not be accurately predicted, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers, markets and economies.
Accounting Pronouncements	Accounting Pronouncements Recently adopted accounting pronouncements In December 2019, the Financial Accounting Standards Board ("FASB") issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which is intended to simplify various aspects related to accounting for income taxes. We adopted the standard on January 1, 2021, on a modified retrospective basis. The adoption of this standard had no impact on our Unaudited Condensed Consolidated Financial Statements. In October 2020, the FASB issued ASU No. 2020-10, Codification Improvement s. ASU 2020-10 provides amendments to a wide variety of topics in the FASB’s Accounting Standards Codification, which applies to all reporting entities within the scope of the affected accounting guidance. We adopted the standard on January 1, 2021 on a retrospective basis. The adoption of this standard had no impact on our Unaudited Condensed Consolidated Financial Statements. Recently issued accounting pronouncements not yet adopted From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the recently issued standards that are not yet effective will not have a material impact on our Unaudited Condensed Consolidated Financial Statements upon adoption. In May 2021, FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the Emerging Issues Task Force . The standard establishes a principles-based framework in accounting for modifications of freestanding equity-classified written call options on the basis of the economic substance of the underlying transaction. The standard also requires incremental financial statement disclosures. The standard affects entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years with early adoption is permitted by applying the standard as of the beginning of the fiscal year that includes that interim period. The standard may be adopted prospectively for modifications or exchanges occurring on or after the effective date. We will evaluate modifications of equity-classified written call options to determine applicability of the standard on occurrence; however, we believe that the adoption of ASU 2021-04 will have no impact on our Unaudited Condensed Consolidated Financial Statements and related disclosures. In August 2020, FASB issued ASU No. 2020-06 Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40) No. 2020-06 August 2020 Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , to reduce the complexity and to simplify the accounting for convertible debt instruments and convertible preferred stock, and the derivatives scope exception for contracts in an entity's own equity. In addition, the guidance on calculating diluted earnings per share has been simplified and made more internally consistent. The standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years with early adoption permitted for fiscal years beginning December 15, 2020. The standard may be adopted on a modified retrospective or fully retrospective method of transition and on adoption, entities may irrevocably elect the fair value option in accordance with Subtopic 825-10, Financial Instruments—Overall, for any financial instrument that is a convertible security. We believe that the adoption of ASU 2020-06 will have no impact on our Unaudited Condensed Consolidated Financial Statements and related disclosures. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The standard provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions in which the reference LIBOR or another reference rate are expected to be discontinued as a result of the Reference Rate Reform. The standard is effective for all entities and can be adopted no later than December 1, 2022, with early adoption permitted. The standard may be adopted on a prospective basis. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to elect optional expedients for contract modification; however, we believe that the adoption of ASU 2020-04 will have no impact on our Unaudited Condensed Consolidated Financial Statements and related disclosures. There have been no other recent accounting pronouncements or changes in accounting pronouncements during the three and six months ended June 30, 2021, as compared to the recent accounting pronouncements described in herein, that are of significance or potential significance to us.
Segment Information	Segment Information We manage our business as two business segments: Performance Enzymes and Novel Biotherapeutics. Our chief operating decision maker ("CODM") is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	Segment information is as follows (in thousands): Three months ended June 30, 2021 Three months ended June 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product Revenue $ 14,717 $ — $ 14,717 $ 4,504 $ — $ 4,504 Research and development revenue 6,868 3,868 10,736 3,002 7,461 10,463 Total revenues $ 21,585 $ 3,868 $ 25,453 $ 7,506 $ 7,461 $ 14,967 Primary geographical markets: Americas 3,703 2,141 $ 5,844 $ 1,173 $ 5,733 $ 6,906 EMEA 4,442 1,727 6,169 1,586 1,728 3,314 APAC 13,440 — 13,440 4,747 — 4,747 Total revenues $ 21,585 $ 3,868 $ 25,453 $ 7,506 $ 7,461 $ 14,967 Six months ended June 30, 2021 Six months ended June 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product Revenue $ 24,943 $ — $ 24,943 $ 9,604 $ — $ 9,604 Research and development revenue 10,872 7,670 18,542 8,775 11,258 20,033 Total revenues $ 35,815 $ 7,670 $ 43,485 $ 18,379 $ 11,258 $ 29,637 Primary geographical markets: Americas $ 6,574 $ 4,199 $ 10,773 $ 4,171 $ 7,960 $ 12,131 EMEA 8,979 3,471 12,450 5,987 3,298 9,285 APAC 20,262 — 20,262 8,221 — 8,221 Total revenues $ 35,815 $ 7,670 $ 43,485 $ 18,379 $ 11,258 $ 29,637
Contract with Customer	The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands): June 30, 2021 December 31, 2020 Contract assets $ 4,528 $ 4,526 Unbilled receivables $ 12,417 $ 10,942 Contract costs $ 86 $ 90 Contract liabilities: deferred revenue $ 5,479 $ 4,791 We recognized the following revenues (in thousands): Three months ended June 30, Six months ended June 30, Revenue recognized in the period for: 2021 2020 2021 2020 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 1,239 $ 4,272 $ 1,391 $ 57 Changes in the period: Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods 4,306 1,357 4,336 637 Performance obligations satisfied from new activities in the period - contract revenue 19,908 9,338 37,758 28,943 Total revenues $ 25,453 $ 14,967 $ 43,485 $ 29,637
Performance Obligation, Expected Timing of Satisfaction	The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of June 30, 2021. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of June 30, 2021 (in thousands): Remainder of 2021 2022 2023 2024 and Thereafter Total Product revenue $ — $ 67 $ 67 $ 1,843 $ 1,977 Research and development revenue 1,568 1,388 546 — 3,502 Total revenues $ 1,568 $ 1,455 $ 613 $ 1,843 $ 5,479

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Shares Not Included in Computation of Diluted Net Loss Per Share	The following shares were not considered in the computation of diluted net loss per share because their effect was anti-dilutive (in thousands): Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Shares issuable under the Equity Incentive Plan 5,366 5,289 5,366 5,289

Investments in Non-Marketable_2

Investments in Non-Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Details of Non-marketable Debt Securities	The following table presents balances of the adjusted cost and carrying value and fair value of non-marketable debt security by contractual maturity (in thousands): June 30, 2021 Adjusted Cost and Carrying Value Fair Value Non-marketable debt security due in 1 year or less $ 1,289 $ 1,289 December 31, 2020 Adjusted Cost and Carrying Value Fair Value Non-marketable debt security due in 1 year or less $ 1,000 $ 1,000
Carrying Value of Non-marketable Equity Securities	The following table presents balances of the carrying value of non-marketable equity securities (in thousands): June 30, 2021 December 31, 2020 Non-marketable equity securities $ 3,430 $ 1,450

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured at Fair Value on a Recurring Basis	The following tables present the financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands): June 30, 2021 Level 1 Level 2 Level 3 Total Money market funds $ 111,083 $ — $ — $ 111,083 Non-marketable debt security — — 1,289 1,289 Total $ 111,083 $ — $ 1,289 $ 112,372 December 31, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 127,567 $ — $ — $ 127,567 Non-marketable debt security — — 1,000 1,000 Total $ 127,567 $ — $ 1,000 $ 128,567

Balance Sheets Details (Tables)

Balance Sheets Details (Tables)	6 Months Ended
	Jun. 30, 2021
Balance Sheets Details [Abstract]
Schedule of Cash and Cash Equivalents	Cash equivalents as of June 30, 2021 and December 31, 2020, consisted of the following (in thousands): June 30, 2021 December 31, 2020 Adjusted Cost Estimated Fair Value Adjusted Cost Estimated Fair Value Money market funds (1) $ 111,083 $ 111,083 $ 127,567 $ 127,567 (1) Money market funds are classified in cash and cash equivalents on our consolidated balance sheets. Average Contractual Maturities (in days) is not applicable.
Schedule of Inventory Components	Inventories consisted of the following (in thousands): June 30, 2021 December 31, 2020 Raw materials $ 49 $ 77 Work-in-process 98 82 Finished goods 931 805 Inventories $ 1,078 $ 964
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): June 30, 2021 December 31, 2020 Laboratory equipment $ 28,623 $ 25,468 Leasehold improvements 10,785 10,785 Computer equipment and software 3,283 3,192 Office equipment and furniture 1,246 1,246 Construction in progress 1,736 2,357 Property and equipment 45,673 43,048 Less: accumulated depreciation and amortization (34,441) (33,373) Property and equipment, net $ 11,232 $ 9,675 Depreciation expense included in the Unaudited Condensed Consolidated Statements of Operations was follows (in thousands): Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Depreciation Expense $ 716 $ 462 $ 1,375 $ 900
Schedule of Other Accrued Liabilities	Other accrued liabilities consisted of the following (in thousands): June 30, 2021 December 31, 2020 Accrued purchases $ 5,107 $ 7,170 Accrued professional and outside service fees 3,899 2,589 Other 76 513 Total $ 9,082 $ 10,272

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense	Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Research and development $ 597 $ 471 $ 1,074 $ 894 Selling, general and administrative 2,247 1,468 4,457 3,214 Total $ 2,844 $ 1,939 $ 5,531 $ 4,108
Schedule of Stock-based Compensation Expense by Security Types	The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Stock options $ 682 $ 575 $ 1,347 $ 1,116 RSUs and RSAs 690 610 1,232 1,210 PSUs 573 296 1,043 627 PBOs 899 458 1,909 1,155 Total $ 2,844 $ 1,939 $ 5,531 $ 4,108

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Lease Cost	Lease costs, amounts included in measurement of lease obligations and other information related to non-cancellable operating leases and finance leases were as follows (in thousands): Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Finance lease costs: Amortization of right-of-use assets $ 27 $ 45 $ 53 $ 99 Interest on lease obligations — 1 — 1 Finance lease costs 27 46 53 100 Operating lease cost 1,033 1,032 2,065 2,100 Short-term lease costs (1) 10 16 10 47 Sublease income — — — (55) Total lease cost (2) $ 1,070 $ 1,094 $ 2,128 $ 2,192 (1 ) Short-term lease costs on leases with terms of over one month and less than one year. (2) The Company had no variable lease costs. Other information: Operating Leases Weighted-average remaining lease term (in years) 6.2 years Weighted-average discount rate 6.6 % Six months ended June 30, Cash paid: 2021 2020 Operating cash flows from operating leases $ 2,093 $ 774 Financing cash flows from finance leases $ — $ 60
Operating Lease Maturity	As of June 30, 2021, our maturity analysis of annual undiscounted cash flows of the non-cancellable operating leases are as follows (in thousands): Years ending December 31, Operating Leases 2021 (remaining 6 months) $ 2,104 2022 4,285 2023 4,589 2024 4,726 2025 4,868 Thereafter 8,626 Total minimum lease payments 29,198 Less: imputed interest 5,534 Lease obligations $ 23,664 An estimated maturity analysis of the annual undiscounted cash flows of the lease is as follows (in thousands): Years ending December 31, Operating Lease 2021 (remaining 6 months) $ — 2022 2,463 2023 2,988 2024 3,066 2025 3,145 2026 and thereafter 20,061 Total minimum lease payments $ 31,723
Schedule of Supply and Service Commitments	The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands): Other Commitment Agreement Type Agreement Date Future Minimum Payment Manufacture and supply agreement with expected future payment date of December 2022 April 2016 $ 162 Development and manufacturing services agreements September 2019 1,852 Total other commitments $ 2,014

Segment, Geographical and Oth_2

Segment, Geographical and Other Revenue Information (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting	The following table provides financial information by our reportable business segments along with a reconciliation to consolidated income (loss) before income taxes (in thousands): Three months ended June 30, 2021 Three months ended June 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 14,717 $ — $ 14,717 $ 4,504 $ — $ 4,504 Research and development revenue 6,868 3,868 10,736 3,002 7,461 10,463 Total revenues 21,585 3,868 25,453 7,506 7,461 14,967 Costs and operating expenses: Cost of product revenue 4,318 — 4,318 1,699 — 1,699 Research and development (1) 5,057 7,194 12,251 4,997 5,490 10,487 Selling, general and administrative (1) 3,170 620 3,790 2,375 621 2,996 Total segment costs and operating expenses 12,545 7,814 20,359 9,071 6,111 15,182 Income (loss) from operations $ 9,040 $ (3,946) 5,094 $ (1,565) $ 1,350 (215) Corporate costs (2) (8,610) (5,316) Unallocated depreciation and amortization (741) (506) Loss before income taxes $ (4,257) $ (6,037) Six months ended June 30, 2021 Six months ended June 30, 2020 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 24,943 $ — $ 24,943 $ 9,604 $ — $ 9,604 Research and development revenue 10,872 7,670 18,542 8,775 11,258 20,033 Total revenues 35,815 7,670 43,485 18,379 11,258 29,637 Costs and operating expenses: Cost of product revenue 8,536 — 8,536 4,240 — 4,240 Research and development (1) 11,502 11,799 23,301 10,693 10,415 21,108 Selling, general and administrative (1) 5,988 1,221 7,209 4,720 1,213 5,933 Total segment costs and operating expenses 26,026 13,020 39,046 19,653 11,628 31,281 Income (loss) from operations $ 9,789 $ (5,350) 4,439 $ (1,274) $ (370) (1,644) Corporate costs (2) (16,335) (11,042) Unallocated depreciation and amortization (1,426) (998) Loss before income taxes $ (13,322) $ (13,684) (1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases. (2) Corporate costs include unallocated selling, general and administrative expenses, interest income, and other income (expense), net. The following table provides stock-based compensation expense included in income (loss) from operations (in thousands): Three months ended June 30, 2021 2020 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 1,115 $ 257 $ 1,472 $ 2,844 $ 741 $ 252 $ 946 $ 1,939 Six months ended June 30, 2021 2020 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 2,109 $ 495 $ 2,927 $ 5,531 $ 1,496 $ 494 $ 2,118 $ 4,108
Schedule of Customers that Contributed 10% or More of Total Accounts Receivable	Significant Customers Customers that each accounted for 10% or more of our total revenues were as follows: Percentage of Total Revenues for the Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Customer A 15% * 10% * Customer B 12% * * * Customer C 12% * 13% * Customer D * 16% 17% 20% Customer E * 38% 10% 27% Customer F * 12% * 11% Customer G * * * 13% * Percentage was less than 10% Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows: Percentage of Accounts Receivables as of June 30, 2021 December 31, 2020 Customer A 20% * Customer H 15% * Customer B 15% * Customer D 14% 32% Customer E 10% * Customer G * 25% Customer F * 13% * Percentage was less than 10%
Schedule of Revenues by Geographical Area	Geographic revenues are identified by the location of the customer and consist of the following (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenues Americas $ 5,844 $ 6,906 $ 10,773 $ 12,131 EMEA 6,169 3,314 12,450 9,285 APAC 13,440 4,747 20,262 8,221 Total revenues $ 25,453 $ 14,967 $ 43,485 $ 29,637
Schedule of Long-Lived Assets by Geographical Area	Identifiable long-lived assets by location was as follows (in thousands): June 30, 2021 December 31, 2020 United States $ 31,424 $ 31,176
Schedule of Intangible Assets and Goodwill	Identifiable goodwill by reporting unit was as follows (in thousands): As of June 30, 2021 and December 31, 2020 Performance Enzymes Novel Biotherapeutics Total Goodwill $ 2,463 $ 778 $ 3,241

Allowance for Credit Losses (Ta

Allowance for Credit Losses (Tables)	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
Analysis of Allowance for Credit Losses	The following table summarizes the financial assets allowance for credit losses (in thousands): June 30, 2021 December 31, 2020 Allowance for credit losses $ 74 74
Summary of Accounts Receivable by Aging	The following tables summarize accounts receivable by aging category (in thousands): June 30, 2021 Current 31-60 Days 61-90 Days 91 Days and over Total balance Accounts receivable $ 17,414 $ 83 $ 1,602 $ 389 $ 19,488 December 31, 2020 Current 31-60 Days 61-90 Days 91 Days and over Total balance Accounts receivable $ 13,398 $ 489 $ 7 $ — $ 13,894

Description of Business (Detail

Description of Business (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended	6 Months Ended
	Apr. 30, 2021	Jun. 30, 2020	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2021	Jun. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to acquire other investments					$ 630	$ 1,000
Nestle Health Sciences | CDX-6114
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cumulative catch-up adjustment to revenue, change in measure of progress				$ 3,000
Takeda
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable cash payment			$ 8,500
Molecular Assemblies, Inc. | Series A Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares purchased	1,000,000	1,587,050				1,587,050
Payments to acquire other investments	$ 600	$ 1,000

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Total revenues	$ 25,453	$ 14,967	$ 43,485	$ 29,637
Americas
Disaggregation of Revenue [Line Items]
Total revenues	5,844	6,906	10,773	12,131
EMEA
Disaggregation of Revenue [Line Items]
Total revenues	6,169	3,314	12,450	9,285
APAC
Disaggregation of Revenue [Line Items]
Total revenues	13,440	4,747	20,262	8,221
Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	14,717	4,504	24,943	9,604
Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	10,736	10,463	18,542	20,033
Performance Enzymes
Disaggregation of Revenue [Line Items]
Total revenues	21,585	7,506	35,815	18,379
Performance Enzymes | Americas
Disaggregation of Revenue [Line Items]
Total revenues	3,703	1,173	6,574	4,171
Performance Enzymes | EMEA
Disaggregation of Revenue [Line Items]
Total revenues	4,442	1,586	8,979	5,987
Performance Enzymes | APAC
Disaggregation of Revenue [Line Items]
Total revenues	13,440	4,747	20,262	8,221
Performance Enzymes | Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	14,717	4,504	24,943	9,604
Performance Enzymes | Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	6,868	3,002	10,872	8,775
Novel Biotherapeutics
Disaggregation of Revenue [Line Items]
Total revenues	3,868	7,461	7,670	11,258
Novel Biotherapeutics | Americas
Disaggregation of Revenue [Line Items]
Total revenues	2,141	5,733	4,199	7,960
Novel Biotherapeutics | EMEA
Disaggregation of Revenue [Line Items]
Total revenues	1,727	1,728	3,471	3,298
Novel Biotherapeutics | APAC
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics | Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics | Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	$ 3,868	$ 7,461	$ 7,670	$ 11,258

Revenue Recognition - Contracts

Revenue Recognition - Contracts with Customer (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Contract assets	$ 4,528	$ 4,526
Unbilled receivables	12,417	10,942
Contract costs	86	90
Contract liabilities: deferred revenue	$ 5,479	$ 4,791

Revenue Recognition - Textual (

Revenue Recognition - Textual (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Impairment charges related to contract assets	$ 0	$ 0	$ 0	$ 0

Revenue Recognition - Revenue R

Revenue Recognition - Revenue Recognized During Period (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Performance obligations satisfied	$ 1,239	$ 4,272	$ 1,391	$ 57
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods	4,306	1,357	4,336	637
Performance obligations satisfied from new activities in the period - contract revenue	19,908	9,338	37,758	28,943
Total revenues	$ 25,453	$ 14,967	$ 43,485	$ 29,637

Revenue Recognition - Performan

Revenue Recognition - Performance Obligation (Details) $ in Thousands	Jun. 30, 2021USD ($)
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 5,479
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,568
Expected timing of satisfaction, period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,455
Expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 613
Expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,843
Expected timing of satisfaction, period
Product revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,977
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 0
Expected timing of satisfaction, period	6 months
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 67
Expected timing of satisfaction, period	1 year
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 67
Expected timing of satisfaction, period	1 year
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,843
Expected timing of satisfaction, period
Research and development revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 3,502
Research and development revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,568
Expected timing of satisfaction, period	6 months
Research and development revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 1,388
Expected timing of satisfaction, period	1 year
Research and development revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 546
Expected timing of satisfaction, period	1 year
Research and development revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation	$ 0
Expected timing of satisfaction, period

Net Loss per Share (Details)

Net Loss per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Shares Issuable Under the Equity Incentive Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded as anti-dilutive (shares)	5,366	5,289	5,366	5,289

Investments in Non-Marketable_3

Investments in Non-Marketable Securities - Textual (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Marketable Securities [Line Items]
Interest income from amortization of discount	$ 200,000	$ 0	$ 300,000	$ 0
Change in fair value of embedded bifurcated derivative recognized in other income	57,500
Change in fair value of embedded bifurcated derivative recognized in other expense			10,500
Other expenses		0		0
Unrealized or realized gains or losses	0	0	0	0
Non-marketable equity securities
Marketable Securities [Line Items]
Unrealized or realized gains or losses	$ 0	$ 0	$ 0	$ 0

Investments in Non-Marketable_4

Investments in Non-Marketable Securities - Carrying Value and Fair Value of Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Marketable Securities [Line Items]
Adjusted Cost and Carrying Value	$ 1,289	$ 1,000
Fair Value	1,289	1,000
Non-marketable equity securities
Marketable Securities [Line Items]
Investment in non-marketable equity securities	$ 3,430	$ 1,450

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Summary of financial instruments measured at fair value on a recurring basis
Non-marketable debt security	$ 1,289,000		$ 1,289,000		$ 1,000,000
Total	112,372,000		112,372,000		128,567,000
Convertible Debt
Summary of financial instruments measured at fair value on a recurring basis
Credit losses	0	$ 0	0	$ 0
Other-than-temporary impairment losses	0	$ 0	0	$ 0
Money Market Funds
Summary of financial instruments measured at fair value on a recurring basis
Money market funds	111,083,000		111,083,000		127,567,000
Level 1
Summary of financial instruments measured at fair value on a recurring basis
Total	111,083,000		111,083,000		127,567,000
Level 1 | Money Market Funds
Summary of financial instruments measured at fair value on a recurring basis
Money market funds	111,083,000		111,083,000		127,567,000
Level 3
Summary of financial instruments measured at fair value on a recurring basis
Non-marketable debt security	1,289,000		1,289,000		1,000,000
Total	$ 1,289,000		$ 1,289,000		$ 1,000,000

Balance Sheets Details - Cash a

Balance Sheets Details - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Cash and Cash Equivalents [Line Items]
Adjusted Cost	$ 129,506	$ 149,117	$ 75,649
Money Market Funds
Cash and Cash Equivalents [Line Items]
Adjusted Cost	111,083	127,567
Estimated Fair Value	111,083	127,567
Cash
Cash and Cash Equivalents [Line Items]
Adjusted Cost	$ 18,400	$ 21,500

Balance Sheets Details - Invent

Balance Sheets Details - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Schedule of Inventory Components
Raw materials	$ 49	$ 77
Work-in-process	98	82
Finished goods	931	805
Inventories	1,078	964
Inventory reserves	$ 1,500	$ 1,500

Balance Sheets Details - Proper

Balance Sheets Details - Property and Equipment, net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment	$ 45,673		$ 45,673		$ 43,048
Less: accumulated depreciation and amortization	(34,441)		(34,441)		(33,373)
Property and equipment, net	11,232		11,232		9,675
Depreciation	716	$ 462	1,375	$ 900
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property and equipment	28,623		28,623		25,468
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment	10,785		10,785		10,785
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment	3,283		3,283		3,192
Office equipment and furniture
Property, Plant and Equipment [Line Items]
Property and equipment	1,246		1,246		1,246
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment	$ 1,736		$ 1,736		$ 2,357

Balance Sheets Details - Goodwi

Balance Sheets Details - Goodwill (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Balance Sheet Details [Abstract]
Goodwill	$ 3,241	$ 3,241

Balance Sheets Details - Other

Balance Sheets Details - Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Balance Sheets Details [Abstract]
Accrued purchases	$ 5,107	$ 7,170
Accrued professional and outside service fees	3,899	2,589
Other	76	513
Total	$ 9,082	$ 10,272

Stock-based Compensation - Equi

Stock-based Compensation - Equity Incentive Plans (Details) - 2019 Plan - shares	Jun. 30, 2019	Apr. 22, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant		7,897,144
Maximum number of shares to be issued upon exercise of stock options		14,000,000
Number of shares authorized	8,100,000

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Options (Details)	6 Months Ended
	Jun. 30, 2021
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock	100.00%
Non-Statutory Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock	85.00%
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of voting interests	10.00%
Purchase price of common stock above minimum threshold	110.00%
Award vesting period	4 years
Expiration period of options upon employee's termination of service	3 months
Stock Options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Stock Options | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)	25.00%
Stock Options | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)	75.00%

Stock-based Compensation - Rest

Stock-based Compensation - Restricted Stock Units (Details) - RSUs	6 Months Ended
	Jun. 30, 2021
Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Award vesting rights (percent)	33.00%
Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Award vesting rights (percent)	25.00%

Stock-based Compensation - PSUs

Stock-based Compensation - PSUs and PBOs (Details) - Performance Shares - installment	3 Months Ended			6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of installments				2
Performance awards, threshold level, number of shares, multiplier				0
Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)				50.00%
Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)				50.00%
2021 PSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate				136.00%
2020 PBO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate				68.00%
2020 PSU and PBO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate		88.00%
2020 PSU and PBO | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)		50.00%
2020 PSU and PBO | Tranche Two | Forecast
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)	50.00%
2019 PSU and PBO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate			84.00%
2019 PSU and PBO | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)			50.00%
2019 PSU and PBO | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percent)		50.00%

Stock-based Compensation - St_2

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 2,844	$ 1,939	$ 5,531	$ 4,108
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	682	575	1,347	1,116
Compensation not yet recognized, stock options	4,800		4,800
RSUs and RSAs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	690	610	1,232	1,210
Compensation not yet recognized, share-based awards other than options	4,700		4,700
PSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	573	296	1,043	627
Compensation not yet recognized, share-based awards other than options	1,900		1,900
PBOs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	899	458	1,909	1,155
Compensation not yet recognized, share-based awards other than options	3,300		3,300
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	597	471	1,074	894
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 2,247	$ 1,468	$ 4,457	$ 3,214

Capital Stock (Details)

Capital Stock (Details) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
	May 31, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Equity [Abstract]
Stock options exercised (shares)			212,631	32,749
Weighted average exercise price of stock options exercised (usd per share)			$ 8.03	$ 6.03
Proceeds from exercises of stock options			$ 1,679,000	$ 197,000
PSC
Subsidiary, Sale of Stock [Line Items]
Sale period	3 years
Value of shares for issuance		$ 50,000,000	$ 50,000,000
Commissions as percentage of gross sales price	3.00%
Shares issued (in shares)		0	0
PSC | Maximum
Subsidiary, Sale of Stock [Line Items]
Value of shares for issuance	$ 50,000,000
Commissions and reimbursements of expenses as percentage of gross sales price	8.00%

Commitments and Contingencies -

Commitments and Contingencies - Textual (Details)	Jun. 30, 2017USD ($)	Apr. 30, 2017USD ($)	Feb. 28, 2017USD ($)	Mar. 31, 2021USD ($)ft²reportingUnit	Jun. 30, 2021USD ($)ft²numberOfRenewalOption	Dec. 31, 2020USD ($)	Apr. 30, 2020ft²	Jan. 31, 2020ft²
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²					77,300
Number of options to extend | numberOfRenewalOption					1
Asset retirement obligations					$ 200,000	$ 200,000
Future lease commitment					29,198,000
Term of contract		3 years	3 years
Capital lease obligations incurred		$ 300,000	$ 400,000
Percentage of eligible accounts receivable	80.00%
Indemnification Agreement
Commitments and Contingencies [Line Items]
Loss contingency accrual					0
Term Loan
Commitments and Contingencies [Line Items]
Borrowing capacity	$ 10,000,000
Stated interest rate	3.75%
Basis spread on variable rate (percent)	0.50%
Revolving Credit Facility
Commitments and Contingencies [Line Items]
Borrowing capacity	$ 5,000,000
Stated interest rate	4.25%
Basis spread on variable rate (percent)	1.00%
Demand Deposits
Commitments and Contingencies [Line Items]
Non-current restricted cash					1,100,000	$ 1,100,000
San Carlos, Califiornia
Commitments and Contingencies [Line Items]
Future lease commitment					$ 100,000
200-220 Penobscot
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²					28,200
400 Penobscot
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²					37,900
Renewal term					5 years
501 Chesapeake
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²					11,200
Number of options to extend | numberOfRenewalOption					1
Renewal term					5 years
101 Saginaw
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²								29,900
Sublease
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²							3,400	26,500
San Carlos
Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²				36,593
Number of options to extend | reportingUnit				1
Future lease commitment					$ 31,723,000
Annualized rent				$ 2,500,000
Annual rent increases (as a percent)				3.00%
Lease term				10 years
Renewal term				5 years
Security deposit				$ 500,000
San Carlos | Leaseholds and Leasehold Improvements
Commitments and Contingencies [Line Items]
Tenant improvement allowance				6,300,000
San Carlos | Asset under Construction
Commitments and Contingencies [Line Items]
Tenant improvement allowance				2,700,000
Annualized rent				$ 400,000

Commitments and Contingencies_2

Commitments and Contingencies - Lease Cost (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Lease, Cost [Abstract]
Amortization of right-of-use assets	$ 27,000	$ 45,000	$ 53,000	$ 99,000
Interest on lease obligations	0	1,000	0	1,000
Finance lease costs	27,000	46,000	53,000	100,000
Operating lease cost	1,033,000	1,032,000	2,065,000	2,100,000
Short-term lease cost	10,000	16,000	10,000	47,000
Sublease income	0	0	0	(55,000)
Total lease cost	1,070,000	1,094,000	2,128,000	2,192,000
Variable lease cost	$ 0	$ 0	$ 0	$ 0

Commitments and Contingencies_3

Commitments and Contingencies - Other Lease Information (Details)	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Weighted-average remaining lease term (in years)	6 years 2 months 12 days
Weighted-average discount rate	6.60%

Commitments and Contingencies_4

Commitments and Contingencies - Cash Paid for Lease Obligations (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Operating cash flows from operating leases	$ 2,093	$ 774
Financing cash flows from finance leases	$ 0	$ 60

Commitments and Contingencies_5

Commitments and Contingencies - Maturity Analysis of Operating Lease (Details) $ in Thousands	Jun. 30, 2021USD ($)
Operating Leases
2021 (remaining 6 months)	$ 2,104
2022	4,285
2023	4,589
2024	4,726
2025	4,868
Thereafter	8,626
Total minimum lease payments	29,198
Less: imputed interest	5,534
Lease obligations	$ 23,664

Commitments and Contingencies_6

Commitments and Contingencies - Estimated Maturity Analysis (Details) $ in Thousands	Jun. 30, 2021USD ($)
Operating Leases
2021 (remaining 6 months)	$ 2,104
2022	4,285
2023	4,589
2024	4,726
2025	4,868
2026 and thereafter	8,626
Total minimum lease payments	29,198
San Carlos
Operating Leases
2021 (remaining 6 months)	0
2022	2,463
2023	2,988
2024	3,066
2025	3,145
2026 and thereafter	20,061
Total minimum lease payments	$ 31,723

Commitments and Contingencies_7

Commitments and Contingencies - Other Commitments (Details) - Supply Commitment $ in Thousands	Jun. 30, 2021USD ($)
Other Commitments [Line Items]
Future Minimum Payment	$ 2,014
April 2016
Other Commitments [Line Items]
Future Minimum Payment	162
September 2019
Other Commitments [Line Items]
Future Minimum Payment	$ 1,852

Related Party Transactions - Mo

Related Party Transactions - Molecular Assemblies, Inc. (Details) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended		13 Months Ended
	Apr. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Payments to acquire other investments					$ 630,000	$ 1,000,000
Investment at cost basis			$ 3,430,000		3,430,000		$ 3,430,000	$ 1,450,000
Deferred revenue			5,479,000		5,479,000		5,479,000	4,791,000
Contract assets			4,528,000		4,528,000		4,528,000	4,526,000
Molecular Assemblies, Inc.
Related Party Transaction [Line Items]
Deferred revenue			400,000		400,000		400,000	0
Contract assets			0		0		$ 0	$ 500,000
Molecular Assemblies, Inc. | MCRA
Related Party Transaction [Line Items]
Research and development revenue from transactions with MAI			$ 300,000	$ 0	$ 500,000	$ 0
Series A Preferred Stock | Molecular Assemblies, Inc. | MCRA
Related Party Transaction [Line Items]
Number of shares received in exchange for services			714,171	0	1,428,342	0
Number of shares received in exchange for services							5,443,734
Molecular Assemblies, Inc. | Series A Preferred Stock
Related Party Transaction [Line Items]
Number of shares purchased	1,000,000	1,587,050		1,587,050		1,587,050
Payments to acquire other investments	$ 600,000	$ 1,000,000

Related Party Transactions - As

Related Party Transactions - AstraZeneca PLC (Details) - Director - Transactions with AstraZeneca PLC - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Revenue from related parties	$ 20,000	$ 100,000
Accounts receivable from related parties			$ 0	$ 0

Segment, Geographical and Oth_3

Segment, Geographical and Other Revenue Information - Textual (Details)	6 Months Ended
	Jun. 30, 2021segment
Segment Reporting [Abstract]
Number of operating segments	2
Number of reportable segments	2

Segment, Geographical and Oth_4

Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting Information [Line Items]
Total revenues	$ 25,453	$ 14,967	$ 43,485	$ 29,637
Cost of product revenue	4,318	1,699	8,536	4,240
Research and development	12,826	10,853	24,397	21,820
Selling, general and administrative	12,795	8,522	24,193	17,512
Total costs and operating expenses	29,939	21,074	57,126	43,572
Income (loss) from operations	(4,486)	(6,107)	(13,641)	(13,935)
Unallocated depreciation and amortization	(716)	(462)	(1,375)	(900)
Income (loss) before income taxes	(4,257)	(6,037)	(13,322)	(13,684)
Stock-based compensation	2,844	1,939	5,531	4,108
Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	21,585	7,506	35,815	18,379
Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	3,868	7,461	7,670	11,258
Product revenue
Segment Reporting Information [Line Items]
Total revenues	14,717	4,504	24,943	9,604
Product revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	14,717	4,504	24,943	9,604
Product revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	10,736	10,463	18,542	20,033
Research and development revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	6,868	3,002	10,872	8,775
Research and development revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	3,868	7,461	7,670	11,258
Operating segments
Segment Reporting Information [Line Items]
Total revenues	25,453	14,967	43,485	29,637
Cost of product revenue	4,318	1,699	8,536	4,240
Research and development	12,251	10,487	23,301	21,108
Selling, general and administrative	3,790	2,996	7,209	5,933
Total costs and operating expenses	20,359	15,182	39,046	31,281
Income (loss) from operations	5,094	(215)	4,439	(1,644)
Stock-based compensation	2,844	1,939	5,531	4,108
Operating segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	21,585	7,506	35,815	18,379
Cost of product revenue	4,318	1,699	8,536	4,240
Research and development	5,057	4,997	11,502	10,693
Selling, general and administrative	3,170	2,375	5,988	4,720
Total costs and operating expenses	12,545	9,071	26,026	19,653
Income (loss) from operations	9,040	(1,565)	9,789	(1,274)
Stock-based compensation	1,115	741	2,109	1,496
Operating segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	3,868	7,461	7,670	11,258
Cost of product revenue	0	0	0	0
Research and development	7,194	5,490	11,799	10,415
Selling, general and administrative	620	621	1,221	1,213
Total costs and operating expenses	7,814	6,111	13,020	11,628
Income (loss) from operations	(3,946)	1,350	(5,350)	(370)
Stock-based compensation	257	252	495	494
Operating segments | Product revenue
Segment Reporting Information [Line Items]
Total revenues	14,717	4,504	24,943	9,604
Operating segments | Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	10,736	10,463	18,542	20,033
Corporate, non-segment
Segment Reporting Information [Line Items]
Total costs and operating expenses	(8,610)	(5,316)	(16,335)	(11,042)
Unallocated depreciation and amortization	(741)	(506)	(1,426)	(998)
Income (loss) before income taxes	(4,257)	(6,037)	(13,322)	(13,684)
Stock-based compensation	$ 1,472	$ 946	$ 2,927	$ 2,118

Segment, Geographical and Oth_5

Segment, Geographical and Other Revenue Information - Concentration Risk (Details) - Customer Concentration Risk	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Revenue, Product and Service Benchmark | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	15.00%		10.00%
Revenue, Product and Service Benchmark | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	12.00%
Revenue, Product and Service Benchmark | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	12.00%		13.00%
Revenue, Product and Service Benchmark | Customer D
Concentration Risk [Line Items]
Concentration risk, percentage		16.00%	17.00%	20.00%
Revenue, Product and Service Benchmark | Customer E
Concentration Risk [Line Items]
Concentration risk, percentage		38.00%	10.00%	27.00%
Revenue, Product and Service Benchmark | Customer F
Concentration Risk [Line Items]
Concentration risk, percentage		12.00%		11.00%
Revenue, Product and Service Benchmark | Customer G
Concentration Risk [Line Items]
Concentration risk, percentage				13.00%
Accounts Receivable | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage			20.00%
Accounts Receivable | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage			15.00%
Accounts Receivable | Customer D
Concentration Risk [Line Items]
Concentration risk, percentage			14.00%		32.00%
Accounts Receivable | Customer E
Concentration Risk [Line Items]
Concentration risk, percentage			10.00%
Accounts Receivable | Customer F
Concentration Risk [Line Items]
Concentration risk, percentage					13.00%
Accounts Receivable | Customer G
Concentration Risk [Line Items]
Concentration risk, percentage					25.00%
Accounts Receivable | Customer H
Concentration Risk [Line Items]
Concentration risk, percentage			15.00%

Segment, Geographical and Oth_6

Segment, Geographical and Other Revenue Information - Revenues by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting Information [Line Items]
Total revenues	$ 25,453	$ 14,967	$ 43,485	$ 29,637
Americas
Segment Reporting Information [Line Items]
Total revenues	5,844	6,906	10,773	12,131
EMEA
Segment Reporting Information [Line Items]
Total revenues	6,169	3,314	12,450	9,285
APAC
Segment Reporting Information [Line Items]
Total revenues	$ 13,440	$ 4,747	$ 20,262	$ 8,221

Segment, Geographical and Oth_7

Segment, Geographical and Other Revenue Information - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
United States
Geographic Areas, Long-Lived Assets [Abstract]
Long-lived assets	$ 31,424	$ 31,176

Segment, Geographical and Oth_8

Segment, Geographical and Other Revenue Information - Goodwill (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Goodwill	$ 3,241	$ 3,241
Operating Segments
Segment Reporting Information [Line Items]
Goodwill	3,241	3,241
Operating Segments | Performance Enzymes
Segment Reporting Information [Line Items]
Goodwill	2,463	2,463
Operating Segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Goodwill	$ 778	$ 778

Allowance for Credit Losses - A

Allowance for Credit Losses - Analysis of Allowance for Credit Losses (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Receivables [Abstract]
Allowance for credit losses	$ 74	$ 74

Allowance for Credit Losses - S

Allowance for Credit Losses - Summary of Finance Receivables by Aging Category (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	$ 19,488	$ 13,894
Current
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	17,414	13,398
31-60 Days
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	83	489
61-90 Days
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	1,602	7
91 Days and over
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	$ 389	$ 0